Development and validation of a cost-utility model for Type1 diabetes mellitus

被引:8
作者
Wolowacz, S. [1 ]
Pearson, I. [1 ]
Shannon, P. [2 ]
Chubb, B. [3 ]
Gundgaard, J. [4 ]
Davies, M. [5 ]
Briggs, A. [6 ]
机构
[1] RTI Hlth Solut, Hlth Econ, Manchester, Lancs, England
[2] RTI Hlth Solut, Patient Reported Outcomes, Manchester, Lancs, England
[3] Novo Nordisk Ltd, European Hlth Econ & Outcomes Res, Gatwick, W Sussex, England
[4] Novo Nordisk AS, Hlth Econ & HTA, Bagsvaerd, Denmark
[5] Univ Leicester, Diabet Res Ctr, Leicester, Leics, England
[6] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland
关键词
RISK-FACTORS; COMPLICATIONS; DISEASE; NEUROPATHY; EURODIAB; COHORT; ONSET;
D O I
10.1111/dme.12663
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsTo develop a health economic model to evaluate the cost-effectiveness of new interventions for Type1 diabetes mellitus by their effects on long-term complications (measured through mean HbA(1c)) while capturing the impact of treatment on hypoglycaemic events. MethodsThrough a systematic review, we identified complications associated with Type1 diabetes mellitus and data describing the long-term incidence of these complications. An individual patient simulation model was developed and included the following complications: cardiovascular disease, peripheral neuropathy, microalbuminuria, end-stage renal disease, proliferative retinopathy, ketoacidosis, cataract, hypoglycemia and adverse birth outcomes. Risk equations were developed from published cumulative incidence data and hazard ratios for the effect of HbA(1c), age and duration of diabetes. We validated the model by comparing model predictions with observed outcomes from studies used to build the model (internal validation) and from other published data (external validation). We performed illustrative analyses for typical patient cohorts and a hypothetical intervention. ResultsModel predictions were within 2% of expected values in the internal validation and within 8% of observed values in the external validation (percentages represent absolute differences in the cumulative incidence). ConclusionsThe model utilized high-quality, recent data specific to people with Type1 diabetes mellitus. In the model validation, results deviated less than 8% from expected values. What's new? A simple cost-utility model was developed to evaluate new interventions for Type1 diabetes mellitus by assessing the association between the interventions' effects on mean HbA(1c) and long-term complications and the risk of hypoglycaemic events. High-quality, recently reported data specific to people with Type1 diabetes mellitus were identified by a systematic review. Model validation included review by clinical and economic experts, verification of input data and formulae, and comparison of model predictions with observations from studies used to build the model and other published data.
引用
收藏
页码:1023 / 1035
页数:13
相关论文
共 50 条
[41]   Midkine: Utility as a Predictor of Early Diabetic Nephropathy in Children with Type 1 Diabetes Mellitus [J].
Metwalley, Kotb Abbass ;
Farghaly, Hekma Saad ;
Gabri, Magda Farghali ;
Abdel-Aziz, Safwat Mohamed ;
Ismail, Asmaa Mohamed ;
Raafat, Duaa Mohamed ;
Elnakeeb, Islam Fathy .
JOURNAL OF CLINICAL RESEARCH IN PEDIATRIC ENDOCRINOLOGY, 2021, 13 (03) :293-299
[42]   External validation of a cardiovascular risk model for Omani patients with type 2 diabetes mellitus: a retrospective cohort study [J].
Al Oraimi, Fatema ;
Al Rawahi, Amani ;
Al Harrasi, Amira ;
Albusafi, Sarah ;
Al-Manji, Laila Mohammed ;
Alrawahi, Abdul Hakeem ;
Al Salmani, Asma Ali .
BMJ OPEN, 2023, 13 (11)
[43]   The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus [J].
Pollock, Richard F. ;
Norrbacka, Kirsi ;
Boye, Kristina S. ;
Osumili, Beatrice ;
Valentine, William J. .
JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) :393-402
[44]   Estimating the cost of type 1 diabetes in Ireland [J].
Sharma, Shikha ;
Gillespie, Paddy ;
Hobbins, Anna ;
Dinneen, Sean F. .
DIABETIC MEDICINE, 2022, 39 (05)
[45]   Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations [J].
Galiero, Raffaele ;
Caturano, Alfredo ;
Vetrano, Erica ;
Monda, Marcellino ;
Marfella, Raffaele ;
Sardu, Celestino ;
Salvatore, Teresa ;
Rinaldi, Luca ;
Sasso, Ferdinando Carlo .
DIABETES METABOLIC SYNDROME AND OBESITY, 2023, 16 :3669-3689
[46]   Impact of type 1 diabetes mellitus on academic performance [J].
Meo, Sultan Ayoub ;
Alkahlan, Mohammad Abdulaziz ;
Al-Mubarak, Mohammed Abdul Rahman ;
Al-obayli, Mohammed Saad ;
Melaibary, Bader Abdullah ;
Bin Dous, Abdullah Nasser ;
Alhassoun, Asim Ibrahim .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2013, 41 (03) :855-858
[47]   Atherogenic dyslipidemia in patients with type 1 diabetes mellitus [J].
Chillaron, Juan J. ;
Sales, Maria P. ;
Flores Le-Roux, Juana A. ;
Castells, Ignasi ;
Benaiges, David ;
Sagarra, Enric ;
Pedro-Botet, Juan .
MEDICINA CLINICA, 2013, 141 (11) :465-470
[48]   Clustering of microvascular complications in Type 1 diabetes mellitus [J].
Bjerg, Lasse ;
Hulman, Adam ;
Charles, Morten ;
Jorgensen, Marit Eika ;
Witte, Daniel Rinse .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2018, 32 (04) :393-399
[49]   Development and validation of a risk prediction model for preterm birth in women with gestational diabetes mellitus [J].
Li, Hanbing ;
Gao, Lingling ;
Yang, Xiao ;
Chen, Lu .
CLINICAL ENDOCRINOLOGY, 2024, 101 (03) :206-215
[50]   Risk factors for development and progression of diabetic retinopathy in Dutch patients with type 1 diabetes mellitus [J].
Schreur, Vivian ;
van Asten, Freekje ;
Ng, Heijan ;
Weeda, Jack ;
Groenewoud, Joannes M. M. ;
Tack, Cees J. ;
Hoyng, Carel B. ;
de Jong, Eiko K. ;
Klaver, Caroline C. W. ;
Klevering, B. Jeroen .
ACTA OPHTHALMOLOGICA, 2018, 96 (05) :459-464